UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2007 |
or
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to |
Commission File No. 0-19731
GILEAD SCIENCES, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 94-3047598 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(IRS Employer Identification No.) | |
333 Lakeside Drive, Foster City, California | 94404 | |
(Address of principal executive offices) | (Zip Code) |
650-574-3000
Registrants Telephone Number, Including Area Code
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. (Check one):
Large accelerated filer x | Accelerated filer ¨ | Non-accelerated filer ¨ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
Number of shares outstanding of the issuers common stock, par value $0.001 per share, as of April 30, 2007: 466,916,711
Explanatory Note
This Amendment No. 1 on Form 10-Q/A is an amendment to the Registrants Quarterly Report on Form 10-Q for the period ended March 31, 2007 (the Report) filed with the Securities and Exchange Commission on May 4, 2007. This Form 10-Q/A is being filed for the sole purpose of correcting a typographical error on the cover page in the number of shares outstanding of the Registrants common stock as of April 30, 2007 which should be 466,916,711 instead of 416,916,711. In addition, the Registrant is also including Exhibits 31.1 and 31.2, as required by the filing of this Form 10-Q/A. This Form 10-Q/A does not alter any other part of the content of the Report and does not affect the information originally set forth in the Report, the remaining portions of which have not been amended.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
GILEAD SCIENCES, INC. (Registrant) | ||||||||
Date: May 8, 2007 |
/s/ JOHN C. MARTIN | |||||||
John C. Martin, Ph.D. President and Chief Executive Officer (Principal Executive Officer) | ||||||||
Date: May 8, 2007 |
/s/ JOHN F. MILLIGAN | |||||||
John F. Milligan, Ph.D. Chief Operating Officer and Chief Financial Officer (Principal Financial and Accounting Officer) |
3
Exhibit Index
Exhibit Number |
Description of Document | |
31.1 | Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended | |
31.2 | Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended |
4